Arcutis Biotherapeutics, Inc. (ARQT)
Nasdaq: ARQT · Pharmaceutical Preparations · Westlake Village, CA · filing with the SEC since 2019
Who owns Arcutis Biotherapeutics, Inc.
As filed with the SECHolders of 5% or more
4
Blackrock, Inc. holds 14.1% of Common Stock, as its SCHEDULE 13G/A filed Oct 5, 2026 says.
Directors and officers
15
report now, of 31 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 5, 2026 · Common Stock
Patrick J. Heron
SCHEDULE 13D/A · filed Aug 20, 2025 · Common Stock, par value $0.0001 per share
Rubric Capital Management LP
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, $0.0001 par value per share
Polar Capital Holdings Plc
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, $0.001 par value per share · 4.2% in Aug 14, 2025
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK · reported falling below 5%, from 5.1% in May 12, 2026
Prudential Financial, Inc.
SCHEDULE 13G/A · filed May 8, 2026 · Common · reported falling below 5%, from 5.7% in Feb 13, 2026
Jennison Associates LLC
SCHEDULE 13G/A · filed May 6, 2026 · Common Stock · reported falling below 5%, from 5.5% in Jan 30, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What ARQT reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Ducentis Biotherapeutics LTD Equity Interests
A company bought · asset acquisition · owns, named in the 10-K filed Feb 25, 2026
1 subsidiary in 1 country, from the list filed with the 10-K filed Feb 25, 2026.
Insider tradesForm 4
73sales
0purchases
62sales on a scheduled plan
11people selling
$16.1Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 4, 2025 to Nov 4, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 4, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window11 of 41 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Matsuda Masaru | EVP, Chief Legal Officer | 18 | $3.4M | 18 | 0 | $0 |
| Watanabe Todd Franklin | See Remarks | 8 | $3.3M | 7 | 0 | $0 |
| Welgus Howard G. | Chief Medical Officer | 12 | $2.1M | 12 | 0 | $0 |
| Burnett Patrick | EVP, Chief Medical Officer | 17 | $2.0M | 13 | 0 | $0 |
| Curran Terrie | director | 3 | $1.0M | 0 | 0 | $0 |
| Leonard Keith R | director | 1 | $1.0M | 1 | 0 | $0 |
| Edwards Larry Todd | Reporting Person's title: EVP, Chief Commercial Officer | 4 | $900,000 | 3 | 0 | $0 |
| Lin Sue-Jean | director | 2 | $900,000 | 1 | 0 | $0 |
| Krishnamohan Neha | director | 2 | $900,000 | 2 | 0 | $0 |
| Gilbert Halley E | director | 1 | $500,000 | 0 | 0 | $0 |
| Vairavan Latha | SVP Chief Financial Officer | 5 | $100,000 | 5 | 0 | $0 |